The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma.
 
Paul B. Chapman
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Momenta Pharmaceuticals; Provectus
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Dirk Schadendorf
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Jean Jacques Grob
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Antoni Ribas
Stock and Other Ownership Interests - Arcus Ventures; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; Merck; Novartis
 
Felix Kiecker
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
Research Funding - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Caroline Dutriaux
No Relationships to Disclose
 
Lev V. Demidov
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Expert Testimony - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Celeste Lebbe
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Novartis
 
Christian U. Blank
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Ralf Gutzmer
Honoraria - Almirall; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Almirall; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Johnson & Johnson (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Michael Millward
Consulting or Advisory Role - Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Richard Kefford
Honoraria - Bristol-Myers Squibb; Merck; Novartis
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); TEVA (Inst)
Speakers' Bureau - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Yingjie Huang
Employment - Novartis
Stock and Other Ownership Interests - Bristol-Myers Squibb; GlaxoSmithKline; Novartis
 
Ying Zhang
Employment - Novartis
 
Matthew Squires
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Bijoyesh Mookerjee
Employment - GlaxoSmithKline; Novartis
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche